Skip to main content
. 2024 Oct 14;148(1):53. doi: 10.1007/s00401-024-02805-y

Fig. 2.

Fig. 2

Left: graphical neuroanatomical representation of the main focus of anti-IgLON5 disease neuropathology and possible related clinical symptoms. Right: grouped analysis and heat map; source of variations: tau burden (0 = absent or mild; 1 = moderate or prominent) and neurodegeneration (mild/moderate vs severe) (two-way ANOVA, source of variation: anatomical region: p = 0.0004; degree of neurodegeneration: p < 0.0001)